Treatment of Staphylococcus aureus Nasal Carriers in Continuous Ambulatory Peritoneal Dialysis With Mupirocin: Long-term Results

Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP)

“…In PD, nasal mupirocin decreases exit-site and tunnel infection but not peritonitis [58,59]. Application is, however, also related to an increase in MIC90 and frequent recolonization [60]. According to ERBP, there is not enough evidence to propagate nasal antibiotic ointment in a haemodialysis setting.…”

Determinants of Acquisition and Carriage ofStaphylococcus aureusin Infancy

“…The rising prevalence of antibiotic-resistant strains, such as methicillin-resistant S. aureus and S. aureus with reduced susceptibility to glycopeptides (15,17,22), increases the need to prevent disease through the identification and modification of risk factors. Three sets of observations indicate that nasal carriage of S. aureus is an important risk factor for sepsis with this organism: carriers have higher rates of infection than noncarriers (16,29,30,31); the strain causing infection is usually the carriage strain in a given individual (16,18,28,31); and eradication of carriage reduces nosocomial infection (2,10,20,31). Temporary eradication of S. aureus in those at high risk of sepsis is desirable but relies on the unlikely premise of sustained susceptibility to antibiotics such as mupirocin.…”

Identification of Targets for Prevention of Peritoneal Catheter Tunnel and Exit-Site Infections in Low Incidence Settings

“…On the other hand, and despite our long-term experience in screening and management (22), SAu carriage was still an independent predictor of TESI by the same bacteria. Several factors may have contributed to the persistence of this association.…”